CHICAGO--(BUSINESS WIRE)--April 12, 2004--NovaMed, Inc. (Nasdaq: NOVA - News) today announced that Robert J. Kelly has joined its Board of Directors.
Mr. Kelly has over 30 years experience as a senior financial executive including 25 years with an international information technology company, Bull HN Information Systems, Inc., and four years with a global medical products company, Summit Autonomous, Inc. Summit Autonomous specialized in excimer lasers and other products used to treat vision problems. Mr. Kelly received his M.B.A. from Harvard Business School with concentration in finance and information systems.
"We are very pleased that Bob Kelly will be joining our Board," commented Stephen J. Winjum, NovaMed Chairman, President and Chief Executive Officer. "With his extensive experience in finance, accounting and information systems as well as his industry specific experience, he will make a great addition to NovaMed," said Winjum.
NovaMed acquires, develops and operates ambulatory surgery centers in partnership with physicians. NovaMed currently owns a majority interest in 19 centers located in 11 states. NovaMed's executive offices are located in Chicago, Illinois.
This press release contains forward-looking statements that relate to possible future events. These statements are based on management's current expectations and are subject to risks and uncertainties, which could cause our actual results to differ materially from those expressed or implied in this press release. These risks and uncertainties relate to our business, our industry and our common stock and include: our ability to acquire, develop or manage a sufficient number of profitable surgical facilities, including facilities that are not exclusively dedicated to eye related procedures; reduced prices and reimbursement rates for surgical procedures; our ability to maintain successful relationships with the physicians who use our surgical facilities; our future profitability could decrease because of existing agreements with physicians that may require us to sell additional equity interests in our ASCs at varying future intervals; the application of existing or proposed government regulations, or the adoption of new laws and regulations, that could limit our business operations and require us to incur significant expenditures; the continued acceptance of laser vision correction and other refractive surgical procedures; and demand for elective surgical procedures generally and in response to a protracted economic downturn. Readers are encouraged to review a more complete discussion of the factors affecting NovaMed's business and prospects in its filings with the Securities and Exchange Commission, including the company's 2003 Form 10-K filed on March 29, 2004. Readers should not place undue reliance on any forward-looking statements. Except as required by the federal securities laws, NovaMed undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changing circumstances or any other reason after the date of this press release.
NovaMed, Inc. Scott T. Macomber, 312-664-4100 email@example.com
Source: NovaMed, Inc.